

## Record Sales Result for December 2025 Quarter

### Highlights

- **Record December quarter with global sales of US\$6.1 million, up 38% on pcp and 25% on the September 2025 quarter**
- **Global six-month sales of US\$10.9 million, up 29% on pcp**
- **Last Twelve Months (LTM) global sales of ~US\$21 million (A\$32.2 million), up 24% on prior twelve months and three times higher than the industry growth rate of ~8%<sup>(1)</sup>**
- **Six consecutive halves of sales growth in the USA at a CAGR of ~40%**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**) is pleased to report a record sales result for the December 2025 quarter and continued strong growth for the six months ended 31 December 2025. These results are subject to audit.

### Sales Performance

The December quarter result of US\$6.1 million reflects continued strong demand in the United States, supported by consistent growth in Rest of World markets. The iTrack technology has now been used in approximately 180,000 surgical cases worldwide. Its minimally invasive, rejuvenative method of action is becoming increasingly recognised by more surgeons as our commercial efforts continue. Sales growth in the twelve months to 31 December 2025 was 24% up on the prior year. This is three times the industry growth rate of ~8% estimated by Marketscope<sup>(1)</sup>.

### Regional Performance Summary (US\$'000s)<sup>(2)</sup>

US\$'000's (unaudited)	Q2FY25 (3 mths to Dec 24)	Q2FY26 (3 mths to Dec 25)	H1FY25 (6 mths to Dec 24)	H1FY26 (6 mths to Dec 25)	Growth on Qtr PCP	Growth on Half PCP
USA	3,333	4,498	6,476	8,559	35%	32%
Germany	512	503	870	877	-2%	1%
<b>Direct</b>	<b>3,845</b>	<b>5,001</b>	<b>7,346</b>	<b>9,436</b>	<b>30%</b>	<b>28%</b>
ROW	210	469	329	816	123%	148%
<b>Sales (excl China)</b>	<b>4,055</b>	<b>5,470</b>	<b>7,675</b>	<b>10,252</b>	<b>35%</b>	<b>34%</b>
China	350	603	710	603	72%	-15%
<b>Group</b>	<b>4,405</b>	<b>6,073</b>	<b>8,385</b>	<b>10,855</b>	<b>38%</b>	<b>29%</b>

Sales results in China in H1FY26 do not include any sales of iTrack™ Advance, which was approved for sale in China in September 2025. Sales are expected to commence in 2026.


### Last Twelve Months (LTM) Revenue

Group revenue for the twelve months ended 31 December 2025 reached **~US\$21 million**, representing **24%** growth on the prior twelve-month period. Growth was led by the United States (USA) and Rest of World (ROW) markets.

	LTM Dec 2024 (US\$'000's)	LTM Dec 2025 (US\$'000's) <sup>(2)</sup>	Growth	LTM Dec 2025 (A\$'000's) <sup>(3)</sup>
USA	12,777	16,272	27%	25,033
Germany	1,720	1,835	7%	2,823
<b>Direct</b>	<b>14,497</b>	<b>18,107</b>	<b>25%</b>	<b>27,856</b>
ROW	1,020	1,788	75%	2,750
<b>Sales (excl China)</b>	<b>15,516</b>	<b>19,895</b>	<b>28%</b>	<b>30,606</b>
China	1,385	1,053	-24%	1,620
<b>Group</b>	<b>16,901</b>	<b>20,948</b>	<b>24%</b>	<b>32,226</b>

### USA sales growth summary

The six months to 31 December 2025 delivered the sixth consecutive half of sales growth since the launch of iTrack™ Advance in the USA. The compounded annualised growth rate across this period is **~40%**.



## Footnotes

- (1) Marketscope Glaucoma Surgical Devices Report August 2025: 2024 to 2025 growth rate for "Tube shunts, Microstents, Subconjunctival shunts, Canaloplasty, Goniotomy"
- (2) Based on management sales records, not audited
- (3) Based on FX rate of A\$1.00 = US\$0.65

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information please contact:

<b>Company</b>	<b>Investors</b>
Tom Spurling	Mark Flynn
Managing Director	Investor Relations
+61 417 818 658	+61 416 068 733
<a href="mailto:tspurling@nova-eye.com">tspurling@nova-eye.com</a>	<a href="mailto:mflynn@nova-eye.com">mflynn@nova-eye.com</a>

---

## ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:  
[www.nova-eye.com](http://www.nova-eye.com)